Zaja; Mirko

Patent Applications and Registrations

Patent applications and USPTO patent grants for Zaja; Mirko.The latest application filed is for "il-17 and ifn-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation".

Company Profile

2.11.12

Zaja; Mirko - Augsburg DE
ZAJA; Mirko - Muenchen DE
Zaja; Mirko - Munich DE
ZAJA; Mirko - Munchen DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation Grant 11,292,788 - Felding , et al. April 5, 2	2022-04-05
IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation App 20210061796 - FELDING; Jakob ; et al.	2021-03-04
Kv1.3 Inhibitors And Their Medical Application App 20200377514 - TASLER; Stefan ; et al.	2020-12-03
KV1.3 inhibitors and their medical application Grant 10,822,345 - Tasler , et al. November 3, 2	2020-11-03
Kv1.3 Inhibitors And Their Medical Application App 20200339592 - TASLER; Stefan ; et al.	2020-10-29
Kv1.3 inhibitors and their medical application Grant 10,723,743 - Tasler , et al.	2020-07-28
Kv1.3 Inhibitors And Their Medical Application App 20190185483 - TASLER; Stefan ; et al.	2019-06-20
2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors Grant 10,005,769 - Leban , et al. June 26, 2	2018-06-26
Kv1.3 Inhibitors And Their Medical Application App 20180051034 - TASLER; Stefan ; et al.	2018-02-22
Bifluorodioxalane-amino-benzimidazole Kinase Inhibitors For The Treatment Of Cancer, Autoimmuneinflammation And Cns Disorders App 20170240556 - LEBAN; Johann ; et al.	2017-08-24
Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders Grant 9,580,438 - Leban , et al. February 28, 2	2017-02-28
2,3-dihydrobenzofuran-5yl Compounds As Dyrk Kinase Inhibitors App 20160137637 - LEBAN; Johann ; et al.	2016-05-19
Bifluorodioxalane-amino-benzimidazole Kinase Inhibitors For The Treatment Of Cancer, Autoimmuneinflammation And Cns Disorders App 20150158878 - Leban; Johann ; et al.	2015-06-11
Novel Substituted Bicyclic Heterocyclic Compounds As Gamma Secretase Modulators App 20150094311 - GIJSEN; HENRICUS JACOBUS MARIA ; et al.	2015-04-02
Substituted bicyclic heterocyclic compounds as gamma secretase modulators Grant 8,946,426 - Gijsen , et al. February 3, 2	2015-02-03
Substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators Grant 8,772,504 - Gijsen , et al. July 8, 2	2014-07-08
Heterocyclic amides as modulators of TRPA1 Grant 8,614,201 - Berthelot , et al. December 24, 2	2013-12-24
Heterocyclic Amides As Modulators Of Trpa1 App 20120083474 - Berthelot; Didier Jean-Claude ; et al.	2012-04-05
Novel Substituted Benzoxazole, Benzimidazole, Oxazolopyridine And Imidazopyridine Derivatives As Gamma Secretase Modulators App 20120022090 - Gijsen; Henricu Jacobus Maria ; et al.	2012-01-26
Novel Substituted Bicyclic Heterocyclic Compounds As Gamma Secretase Modulators App 20110281881 - Gijsen; Henricus, Jacobus, Maria ; et al.	2011-11-17

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.